The funding priciples of the Patient Access Partnership were agreed by the Partners at the Partnership Assembly in December 2014 as follows:


General/operational funding: In addition to EU funding, additional funding of the partnership will be provided through foundations, other public funds, and associations (such as other NGOs, professional and industry associations), in accordance with respective codes of conduct. There will therefore be no general funding from individual pharmaceutical or other companies.

    Projects funding: Concrete projects will be developed in cooperation with interested partners on topics of common interest and according to the priorities and the work streams of the Patient Access Partnership. The projects will be funded through the general and Institutional funding mechanisms and rules and through co-funding by the project partners, in accordance with respective codes of conduct.


    2015 funding status: Currently, the Patient Access Partnership is funded by unrestricted grants from the European Generic and Biosimilar Medicines Association (EGA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in accordance with its constitution, and other trade associations. The accounts of the first year of operation will be audited and presented on the website. Additionally, the work of the Patient Access Partnership is widely supported through in-kind contributions by a variety of PACT′s partners.